Literature DB >> 8192440

Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity data.

J M Hernández1, P Conforti.   

Abstract

Multivariate techniques such as principal component analysis or similar factor analysis help in analyses of the simultaneous interrelationships among several variables. A comparative multivariate analysis on the in vitro activities of eight antimicrobial agents, including the novel molecule daptomycin, is presented. Multivariate analysis detects components or factors and establishes connections among antimicrobial agents on the basis of their different levels of participation in each factor. The first principal component was dominated by vancomycin, teicoplanin, and rifampin (0.94344, 0.92792, and 0.72127, respectively). The second principal component showed strong effects from imipenem, gentamicin, and cephalothin (0.87922, 0.86126, and 0.68870, respectively). Daptomycin stood out alone in the third principal component (0.83983). The first three components defined 81.5% of the total variance and could easily be represented graphically in a three-dimensional scatter plot. In this graphic representation, the eight antimicrobial agents clustered in three different spatial regions; daptomycin occupied a separate spatial position. The use of multivariate analysis offers a different approach to determination of the in vitro activities of new antimicrobial agents and adds some new data on the relationships among different classes. Notwithstanding its limitations, the application of these methods in microbiology and drug development could be an additional tool for use in processing information.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192440      PMCID: PMC284423          DOI: 10.1128/AAC.38.2.184

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Susceptibility of Clostridium difficile to LY146032.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

2.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

Authors:  W E Alborn; N E Allen; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  In vitro activity of LY146032 (daptomycin), a new peptolide.

Authors:  F Ehlert; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.

Authors:  J H Jorgensen; L A Maher; J S Redding
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

8.  Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.

Authors:  R L Hodinka; K Jack-Wait; N Wannamaker; T P Walden; P H Gilligan
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

9.  A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation.

Authors:  M Debono; M Barnhart; C B Carrell; J A Hoffmann; J L Occolowitz; B J Abbott; D S Fukuda; R L Hamill; K Biemann; W C Herlihy
Journal:  J Antibiot (Tokyo)       Date:  1987-06       Impact factor: 2.649

10.  Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

Authors:  E Bingen; N Lambert-Zechovsky; R Leclercq; C Doit; P Mariani-Kurkdjian
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

View more
  1 in total

1.  Identifying patient-level risk factors associated with non-β-lactam resistance outcomes in invasive MRSA infections in the United States using chain graphs.

Authors:  William J Love; C Annie Wang; Cristina Lanzas
Journal:  JAC Antimicrob Resist       Date:  2022-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.